Patent ID: 8354433
Filing Date: 2013-01-15
Classification: A61K,A61P,C07D,Y02A

Abstract:
1. A method for the treatment or amelioration of a disease or medical condition caused by a viral infection, comprising administering to a subject in need thereof an effective amount of a dihydroorotate-dehydrogenase inhibitor of formula (I) wherein A is furan, thiophene, phenyl, cyclopentenyl, cyclopentadienyl, pyridyl or dihydrothiophene; L is a single bond; D is O, or S; Z 1 is O; Z 2 is O; R′ independently represents H, —CO 2 R″, —CONR″R′″, —CR″O, —SO 2 NR″, —NR″—CO-haloalkanyl, haloalkenyl, haloalkynyl, —NO 2 , —NR″—SO 2 -haloalkanyl, haloalkenyl, haloalkynyl, —NR″—SO 2 -alkanyl, —NR″—SO 2 -alkenyl, —NR″—SO 2 -alkynyl, —SO 2 -alkanyl, —SO 2 -alkenyl, —SO 2 -alkynyl, —NR″—CO-alkanyl, —NR″—CO-alkenyl, —NR″—CO-alkynyl, —CN, alkanyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aminoalkanyl, aminoalkenyl, aminoalkynyl, alkanylamino, alkenylamino, alkynylamino, alkanyloxy, alkenyloxy, alkynyloxy, -cycloalkyloxy, —OH, —SH, alkanylthio, alkenylthio, alkynylthio, hydroxyalkanyl, hydroxyalkenyl, hydroxyalkynyl, hydroxyalkanylamino, hydroxyalkenylamino, hydroxyalkynylamino, halogen, haloalkanyl, haloalkenyl, haloalkynyl, haloalkanyloxy, haloalkenyloxy, haloalkynyloxy, aryl, aralkyl or heteroaryl; R″ independently represents hydrogen, haloalkanyl, haloalkenyl, haloalkynyl, hydroxyalkanyl, hydroxyalkenyl, hydroxyalkynyl, alkanyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aminoalkanyl, aminoalkenyl or aminoalkynyl; R′″ independently represents H or alkanyl; R 2 is OR 6 ; R 3 is H; R 6 is H; R 8 is hydrogen; E is phenyl or pyridyl, each of which is optionally substituted by one or more substituents R′; Y is phenyl, which is optionally substituted by one or more substituents R′; m is 1; n is 1; q is 0 or 1; r is 1; and t is 0, or a pharmacologically tolerable salt thereof, or a physiologically functional derivative thereof, which is an ester, phosphate or sulfate modification of a hydroxyl group of a compound of formula I, an ester or amide modification of a carboxylic group of a compound of formula I, or an imine, amide or urea modification of an amino group of a compound of formula I, wherein the viral infection is caused by a virus selected from the group consisting of Human Immunodefficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Influenza, BK-Polyomavirus (BKV), Human Cytomegalo Virus (HCMV), Rift Valley Fever Virus (RVFV), Norovirus (NV), Lassa Virus (LV), Ebolavirus (EBOV), West Nile Virus (WNV), Dengue Virus (DV), Human Respiratory Syncytial Virus (RSV), and Yellow fever virus (YFV).